Drug Development Prospecting: Will Sirtris' Pipeline Pay Dividends at FDA?
This article was originally published in RPM Report
Executive Summary
GlaxoSmithKline went out on a limb by paying $720 million for Sirtris' relatively untested enzyme technology. How FDA evaluates the first-in-class therapy will determine whether GSK was pound wise or pound foolish. Two former FDA reviewers weigh in on how the company can make the most from its investment.
You may also be interested in...
Sirtris Satisfies GSK's M&A Appetite
Pathway-oriented platforms are rare, and dealmaking around them can be complicated: partner too early or for too little and you risk giving away the store. But Sirtris pulled it off, via M&A, when GSK tendered a whopping $720 million for it in April. The deal is another example of Pharma's interest in platform biotechs and its hunger for innovation. But the unique nature of Sirtris's platform -- broad, but around a single set of biological targets -- makes it more one-off than trend-setting.
Drug Development Prospecting: Will Sirtris' Pipeline Pay Dividends at FDA?
GlaxoSmithKline went out on a limb by paying $720 million for Sirtris' relatively untested enzyme technology. How FDA evaluates the first-in-class therapy will determine whether GSK was pound wise or pound foolish. Two former FDA reviewers weigh in on how the company can make the most from its investment.
Knocked Down But Not Out: Recovering From a Refuse to File
A "refusal-to-file" letter typically signals the end of a product's chances of ever getting approved in the US. Some companies, though, have returned from regulatory purgatory to get a review--and even approvals--after meeting FDA's demands.